Study Evaluating Safety And Tolerability, Solid Tumor

NCT ID: NCT00768469

Last Updated: 2018-11-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2011-01-31

Brief Summary

This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.

Conditions

Advanced Malignant Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nera 160 + Pac

Neratinib 160 mg + Paclitaxel 80 mg/m\^2

Group Type: EXPERIMENTAL

Neratinib

Intervention Type: DRUG

Administered orally, continuous, once daily.

Paclitaxel

Intervention Type: DRUG

Administered IV, on days 1, 8, 15 of 28 day cycle.

Nera 240 + Pac

Neratinib 240 mg + Paclitaxel 80 mg/m\^2

Group Type: EXPERIMENTAL

Neratinib

Intervention Type: DRUG

Administered orally, continuous, once daily.

Paclitaxel

Intervention Type: DRUG

Administered IV, on days 1, 8, 15 of 28 day cycle.

Interventions

Neratinib

Administered orally, continuous, once daily.

Intervention Type: DRUG

Paclitaxel

Administered IV, on days 1, 8, 15 of 28 day cycle.

Intervention Type: DRUG

Other Intervention Names

HKI-272

Eligibility Criteria

Inclusion Criteria

• Subjects must have confirmed pathologic diagnosis of a solid tumor that is not curable with available therapy for which HKI-272 plus paclitaxel is a reasonable treatment option.
• At least 1 measurable lesion as defined by RECIST criteria.
• Eastern Cooperative Oncology Group (ECOG) 0 to 1
• LVEF within institutional limits of normal (by MUGA or ECHO).
• Screening laboratory values within the following parameters:

• ANC: greater than or equal to 1.5 x 10E9 /L (1,500 /mm3)
• Platelet count: 10 x 10E10 /L (100,000 /mm3)
• Hemoglobin: greater than or equal to 9.0 g/dL
• Serum creatinine: less than or equal to 1.5 x upper limit of normal (ULN)
• Total bilirubin: less than or equal to 1.5 xULN · AST and ALT: less than or equal to 2.5 xULN (less than or equal to 5 x ULN if liver metastases are present)
• For women of child bearing potential, a negative urine or serum pregnancy test result before study entry. A woman of childbearing potential is one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or other means of birth control or whose sexual partners are either sterile or using contraceptives.
• All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 28 days after the last dose of test article.

Exclusion Criteria

• Prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m^2, epirubicin dose of greater than 800 mg/m^2, or the equivalent dose for other anthracyclines or derivatives.
• Major surgery, chemotherapy, radical (curative intent) radiotherapy, investigational agents, or other cancer therapy within 2 weeks of treatment day 1 or non-recovery from all clinically significant acute adverse effects of prior therapies (excluding alopecia).
• Subjects with bone or skin as the only site of disease.
• Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (subjects with a history of CNS metastases or cord compression are allowable if they have been definitively treated and have been clinically stable for at least three months, and off steroids or anticonvulsants, before first dose of test article).
• QTc interval greater than 0.47 second or known history of QTc prolongation or Torsade de Pointes (TdP).
• Known hypersensitivity to paclitaxel or Cremophor EL (polyoxyethylated castor oil).
• Pregnant or breast feeding women.
• Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade greater than or equal to 2 diarrhea of any etiology at baseline).
• Inability or unwillingness to swallow the HKI-272.
• Treatment with a taxane within 3 months of treatment day 1.
• Pre-existing grade 2 or greater motor or sensory neuropathy.
• Any other cancer within 5 years prior to screening with the exception of contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.
• Presence of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association [NYHA] functional classification of greater than or equal to 2), angina requiring treatment, myocardial infarction within the past 12 months, or any clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention.
• Evidence of significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, make the subject inappropriate for this study. Examples include, but are not limited to, serious active infection (ie, requiring intravenous antibiotic or antiviral agent), uncontrolled major seizure disorder, or significant pulmonary disorder (e.g. interstitial pneumonitis, pulmonary hypertension).

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Puma Biotechnology, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Puma

Role: STUDY_DIRECTOR

Biotechnology

Locations

Investigational Site

Shizuoka, , Japan

Investigational Site

Tokyo, , Japan

Countries

Japan

Other Identifiers

3144A2-1115 / B1891001

Identifier Type: -

Identifier Source: org_study_id